Trials / Completed
CompletedNCT00162851
Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab (MabCampath, Campath) in Patients With B-Cell Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Karolinska University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced B-cell chronic lymphocytic leukemia (B-CLL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alemtuzumab |
Timeline
- Start date
- 2003-04-01
- Completion
- 2006-07-01
- First posted
- 2005-09-13
- Last updated
- 2007-07-25
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00162851. Inclusion in this directory is not an endorsement.